Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial

Stroke

Volumn 40, Issue 11, 2009, Pages 3526-3531

  Goldstein, Larry B ^a   Amarenco, Pierre ^b   Zivin, Justin ^c   Messig, Michael ^d   Altafullah, Irfan ^e   Callahan, Alfred ^f   Hennerici, Michael ^g   MacLeod, Mary J ^h   Sillesen, Henrik ⁱ   Zweifler, Richard ^j   Welch, K Michael A ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

^e Minneapolis Clinic of Neurology   (United States)

^f Neurologic Consultants   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^k ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

more..

Author keywords

ICH; Outcome; Statins; Stroke

Indexed keywords

ATORVASTATIN; PLACEBO;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

EID: 70350548206     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.557330     Document Type: Article

References (35)

1. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
2. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855-1862.
3. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20:541-546.
4. Chen JL, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang CL, Lu M, Katakowski M, Feldkamp CS, Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53: 743-751.
5. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia MD, Molina-Porcel L, Diaz-Manera J, Marti-Vilalta JL. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke. 2004;35:1117-1121.
6. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005;36:1298-1300.
7. Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology. 2005;65:253-258.
8. Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR. Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol. 2005;12:493-498.
9. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graf-fagnino CA, Harrington RA, White HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37:1427-1431.
10. Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke. 2008; 39:1779-1785
11. The SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovasc Dis. 2003;16:389-395.
12. Brott T, Adams HPJ, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870. (Pubitemid 19188240)
13. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
14. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scottish Medical Journal. 1957;2:200-215.
15. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: extension to non-neurologists in the context of a clinical trial. Stroke. 1997;28:307-310.
16. Dewey HM, Donnan GA, Freeman EJ, Sharples CM, Macdonell RAL, McNeill JJ, Thrift AG. Interrater reliability of the National Institutes of Health Stroke Scale: rating by neurologists and nurses in a community-based stroke incidence study. Cerebrovasc Dis. 1999;9: 323-327.
17. Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. Stroke rehabilitation: Analysis of repeated Barthel Index measures. Arch Phys Med Rehabil. 1979;60:14-17.
18. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, Hennerici M, Simunovic L, Zivin JA, Welch KMA. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198-3204.
19. Goldstein LB, Amarenco P, Szarek M, Callahan A, Hennerici M, Sillesen H, Zivin J, Welch KMA. Secondary analysis of hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Neurology. 2008;70:2364-2370.
20. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg. 2004;101: 104-107.
21. Jung KH, Chu K, Jeong SW, Han SY, Lee ST, Kim JY, Kim M, Roh JK. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke. 2004;35:1744-1749.
22. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Car-huapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8:6-12.
23. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Car-huapoma JR. An association of prior statin use with decreased perihe-matomal edema. Neurocrit Care. 2008;8:13-18.
24. FitzMaurice E, Wendell L, Snider R, Schwab K, Chanderraj R, Kinnecom C, Nandigam K, Rost NS, Viswanathan A, Rosand J, Greenberg SM, Smith EE. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008;39:2151-2154.
25. Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92:1386-1398.
26. Kretz A, Schmeer C, Tausch S, Isenmann S. Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis. 2006; 21:421-430.
27. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003;34:157-163.
28. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
29. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34:551-557.
30. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
31. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442-2449.
32. Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T, Qiu J, Amin-Hanjani S, Huang PL, Liao JK, Lo EH, Moskowitz MA. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:722-729.
33. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
34. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, Duckwiler GR, Vinuela F, Pineda S, Liebeskind DS. Statin enhancement of collat-eralization in acute stroke. Neurology. 2007;68:2129-2131.
35. Lu D, Qu C, Goussev A, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24: 1132-1146.